Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.

Ruben A. Mesa

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Myelofibrosis with myeloid metaplasia (MMM) is a progressive, clonal, and lethal myeloproliferative disorder with a variable prognosis. The only potentially curative therapy for MMM is allogeneic stem cell transplantation, but this therapy is too toxic for older patients and inappropriate for young patients with good prognostic features. A nonmyeloablative or autologous stem cell transplant may broaden the applicability of high-dose therapy for MMM, but the therapy for MMM is palliative in intent and aimed at symptomatic relief. There is no approved therapy for MMM; however, certain agents have been useful for targeted palliation. Myelosuppressive drug therapy, targeted radiation, or splenectomy has decreased symptomatic myeloproliferation (i.e., splenomegaly). MMM-associated cytopenias may be improved by the selective use of growth factors, androgens, and thalidomide. Debilitating constitutional symptoms improve with the pharmacologic blockage of tumor necrosis factor-alpha. Further molecular understanding of MMM is necessary for more effective targeted therapies.

Original languageEnglish (US)
Pages (from-to)264-270
Number of pages7
JournalCurrent hematology reports
Issue number3
StatePublished - May 2003

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.'. Together they form a unique fingerprint.

Cite this